Literature DB >> 18414984

Pulmonary embolism in a patient with multiple myeloma receiving thalidomide-dexamethasone therapy.

Wen-Juei Jeng1, Ming-Chung Kuo2, Lee-Yung Shih2, Pao-Hsien Chu3.   

Abstract

Massive pulmonary embolism is an uncommon complication of multiple myeloma treated with thalidomide-dexamethasone regimen. In 2006, multiple myeloma was diagnosed in a 72-year-old man, who received thalidomide-dexamethasone therapy. In January 2007, echocardiography and computerized tomography identified massive pulmonary embolism in the pulmonary arteries and a deep vein thrombus of the right leg. The patient also had an elevated concentration of B-type natriuretic peptide. After heparinization and warfarin therapy, the patient's condition improved. This is the first report of a patient with a rare complication of pulmonary embolism from thalidomide-treated multiple myeloma.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18414984     DOI: 10.1007/s12185-008-0071-x

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  23 in total

1.  A comparison of vincristine and doxorubicin infusional chemotherapy with methylprednisolone (VAMP) with the addition of weekly cyclophosphamide (C-VAMP) as induction treatment followed by autografting in previously untreated myeloma.

Authors:  N Raje; R Powles; S Kulkarni; S Milan; G Middleton; S Singhal; J Mehta; B Millar; C Viner; J Raymond; J Treleaven; D Cunningham; M Gore
Journal:  Br J Haematol       Date:  1997-04       Impact factor: 6.998

2.  Usefulness of bedside testing for brain natriuretic peptide to identify right ventricular dysfunction and outcome in normotensive patients with acute pulmonary embolism.

Authors:  Filippo Pieralli; Iacopo Olivotto; Simone Vanni; Alberto Conti; Alberto Camaiti; Giacomo Targioni; Stefano Grifoni; Giancarlo Berni
Journal:  Am J Cardiol       Date:  2006-03-20       Impact factor: 2.778

3.  Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients.

Authors:  B Barlogie; R Desikan; P Eddlemon; T Spencer; J Zeldis; N Munshi; A Badros; M Zangari; E Anaissie; J Epstein; J Shaughnessy; D Ayers; D Spoon; G Tricot
Journal:  Blood       Date:  2001-07-15       Impact factor: 22.113

4.  Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy.

Authors:  Michele Cavo; Elena Zamagni; Claudia Cellini; Patrizia Tosi; Delia Cangini; Michele Cini; Lelia Valdrè; Gualtiero Palareti; Luciano Masini; Sante Tura; Michele Baccarani
Journal:  Blood       Date:  2002-09-15       Impact factor: 22.113

5.  Guidelines on the diagnosis and management of multiple myeloma 2005.

Authors:  Alastair Smith; Finn Wisloff; Diana Samson
Journal:  Br J Haematol       Date:  2006-02       Impact factor: 6.998

6.  Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group.

Authors:  S Vincent Rajkumar; Emily Blood; David Vesole; Rafael Fonseca; Philip R Greipp
Journal:  J Clin Oncol       Date:  2005-12-19       Impact factor: 44.544

7.  Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy.

Authors:  Thierry Facon; Jean-Yves Mary; Brigitte Pégourie; Michel Attal; Marc Renaud; Alain Sadoun; Laurent Voillat; Véronique Dorvaux; Cyrille Hulin; Gérard Lepeu; Jean-Luc Harousseau; Jean-Paul Eschard; Augustin Ferrant; Michel Blanc; Frédéric Maloisel; Hubert Orfeuvre; Jean-François Rossi; Isabelle Azaïs; Mathieu Monconduit; Philippe Collet; Bruno Anglaret; Ibrahim Yakoub-Agha; Marc Wetterwald; Houchingue Eghbali; Marie-Christine Vekemans; Hervé Maisonneuve; Jacques Troncy; Bernard Grosbois; Chantal Doyen; Antoine Thyss; Jérome Jaubert; Philippe Casassus; Béatrice Thielemans; Régis Bataille
Journal:  Blood       Date:  2005-09-20       Impact factor: 22.113

Review 8.  The blood coagulation mechanism in multiple myeloma.

Authors:  Maurizio Zangari; Fariba Saghafifar; Paulette Mehta; Bart Barlogie; Louis Fink; Guido Tricot
Journal:  Semin Thromb Hemost       Date:  2003-06       Impact factor: 4.180

9.  Fibrinolytic activity in multiple myeloma.

Authors:  Münci Yağci; Gülsan Türköz Sucak; Rauf Haznedar
Journal:  Am J Hematol       Date:  2003-12       Impact factor: 10.047

10.  Thalidomide alone or with dexamethasone for previously untreated multiple myeloma.

Authors:  Donna Weber; Kim Rankin; Maria Gavino; Kay Delasalle; Raymond Alexanian
Journal:  J Clin Oncol       Date:  2003-01-01       Impact factor: 44.544

View more
  1 in total

1.  A Case of Internal Carotid Artery Thrombosis associated with Thalidomide Administration in Multiple Myeloma.

Authors:  Maria Angela Grima; David James Camilleri
Journal:  Eur J Case Rep Intern Med       Date:  2016-05-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.